Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 20, 2023 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that on June 20, 2023, non-qualified stock option awards to purchase an aggregate of 40,032 shares of its common stock were granted to one new … Read more